Powerful Colon Cancer Treatment with AAIT™

Colon cancer is a significant challenge in oncology and remains as the third leading cause of cancer-related death in the USA [1]. The emergence of Adoptive Autologous Immunotherapy (AAIT™) introduces a groundbreaking approach to treatment for colon cancer patients. At both early and late stages, AAIT™ exemplifies the potential of personalized medicine and seeks to drastically transform outcomes. 

For individuals grappling with advanced colon cancer, the paths of traditional cancer care often reach their limits. AAIT™ seeks to open the gateway of options for people who seem to have hit a roadblock with their standard treatment protocol. This emerging treatment leverages the power of the patient’s immune system with natural killer (NK) and dendritic cells that have been ‘trained’ to identify and destroy your unique strain of cancer. AAIT™ is not palliative care, instead it provides targeted cancer care along with improved tolerance and outcomes for patients.

Recent clinical studies have started to underscore the potential of adoptive immunotherapies in treating advanced colorectal cancer. While challenges remain, the preliminary data indicate favorable survival rates for patients who receive treatments like AAIT™ when compared to standard treatments alone [2, 3]. These findings indicate that adoptive immunotherapy has a transformative potential in the treatment of colon cancer.

In advanced colon cancer, AAIT™ can function alongside other forms of immunotherapy such as checkpoint inhibitors [4]. As well, it can also be used alongside standard chemotherapy or radiation to produce a synergistic effect against metastatic cancer [5]. Clinicians are interested in using chemotherapy to potentiate the antitumor effects of adoptively transferred autologous Natural Killer (NK) cells with early results showing that the treatment is tolerated well and is positive for anti-tumor activity [6]. The synergistic effect of AAIT™ with other forms of treatment is one of its greater strengths when it comes to the tough battle against advanced colon cancer. However, this therapy is also effective against earlier stages of the disease as well.

Personalized medicine is the new frontier of cancer treatment where detailed analysis of a patient’s tumor is used to tailor a unique treatment approach. AAIT™ was created from the outset with a goal of expanding options for personalized medicine for cancer patients, including colon cancer. The specificity of treatment both enhances effectiveness and reduces adverse effects typically associated with conventional therapy.

AAIT™ seeks to leverage detailed genetic insights from tumor cells to forge a more effective and less toxic treatment. Already, personalized cancer treatments like AAIT™ have shown considerable benefits in oncology by aligning the therapy with the genetic profile of both the cancer and the patient, allowing more precise targeting of cancer cells while sparing healthy tissue [7]. Adoptive immunotherapy has been demonstrated to have strong cytotoxic activity against cancer stem-like cells, a subgroup of cancer cells that play a role in the development of resistance against chemotherapy [8]. In earlier stages of colon cancer, a localized application of AAIT™ to leverage its cytotoxic activity could help control the disease before it can progress.

The future of colon cancer treatment looks promising with new technologies like AAIT™. Ongoing research will continue to expand its applicability across different stages of the disease. Integrating AAIT™ into the broader spectrum of colon cancer management, from early to advanced stages, is expected to redefine treatment outcomes for patients. Moving forward, continued exploration of genetic markers and the tumor microenvironment will further refine adoptive immunotherapy and other immunotherapies as well. The increased focus on immunotherapy in cancer underscores a broader shift towards individualized cancer treatment. AAIT™ for colon cancer treatment is a success story for personalized medicine and the potential to transform patient survival and quality of life.

AAIT™ seeks to leverage detailed genetic insights from tumor cells to forge a more effective and less toxic treatment. Already, personalized cancer treatments like AAIT™ have shown considerable benefits in oncology by aligning the therapy with the genetic profile of both the cancer and the patient, allowing more precise targeting of cancer cells while sparing healthy tissue [7]. Adoptive immunotherapy has been demonstrated to have strong cytotoxic activity against cancer stem-like cells, a subgroup of cancer cells that play a role in the development of resistance against chemotherapy [8]. In earlier stages of colon cancer, a localized application of AAIT™ to leverage its cytotoxic activity could help control the disease before it can progress.

The future of colon cancer treatment looks promising with new technologies like AAIT™. Ongoing research will continue to expand its applicability across different stages of the disease. Integrating AAIT™ into the broader spectrum of colon cancer management, from early to advanced stages, is expected to redefine treatment outcomes for patients.

Moving forward, continued exploration of genetic markers and the tumor microenvironment will further refine adoptive immunotherapy and other immunotherapies as well. The increased focus on immunotherapy in cancer underscores a broader shift towards individualized cancer treatment. AAIT™ for colon cancer treatment is a success story for personalized medicine and the potential to transform patient survival and quality of life.

As the landscape of cancer therapy shifts from the standard surgery, chemotherapy, and radiology options, towards advanced immunotherapy and personalize medicine, AAIT™ stands at the front of the pack among these emerging and increasingly verified treatment options. Ongoing research and clinical trials will continue to explore the full potential of AAIT™, increasing its efficacy in addressing both early-stage and advanced stage colon cancer.

We continue to increase our understanding of the tumor microenvironment and overcome the challenges of immune evasion to create a more holistic approach to treating colon cancer.

Integration of AAIT™ with other forms of cancer therapy such as checkpoint inhibitors, chemotherapy, or radiation therapy has a synergistic effect against cancer cells [9]. A multi-faceted approach to cancer therapy may be a promising option for colon cancer patients.

By attacking cancer cells through multiple mechanisms simultaneously, the adaptability of cancer stem cells can be overcome, addressing challenges presented by tumor heterogeneity and an immunosuppressive tumor microenvironment. Looking forward, more biomarkers for tumor response and resistance will continue to be identified which could assist with the “training” of natural killer and dendritic cells used in AAIT™. Additional genetic data could also be used to better select patients who might benefit from AAIT™ or find the best therapies suited for their specific strain of cancer. Not only colon cancer patients, but all patients with a cancer diagnosis may benefit from advanced personalized medicine and immunotherapies in the near future. With AAIT™, Envita hopes to bring you a piece of that future of cancer therapy, today.

1. American Cancer Society. Cancer Facts & Figures 2022. Atlanta: American Cancer Society; 2022.
2. Carluccio, Silvia, et al. “Generation of Tumor-Specific Cytotoxic T-Lymphocytes from the Peripheral Blood of Colorectal Cancer Patients for Adoptive T-Cell Transfer: IMMUNOTHERAPY FOR COLON CANCER.” Journal of Cellular Physiology, vol. 230, no. 7, 2015, pp. 1457–65, https://doi.org/10.1002/jcp.24886.
3. Hunyadi, J., András, C., Szabó, I., Szántó, J., Szluha, K., Sipka, S., ... & Rajnavölgyi, É. (2014). Autologous Dendritic Cell Based Adoptive Immunotherapy of Patients with Colorectal Cancer—A Phase I-II Study. Pathology & Oncology Research, 20, 357-365.
4. Gammelgaard, O. L., Terp, M. G., Kirkin, A. F., Johansen, S., Traynor, S., Vever, H., Guldberg, P., Kodahl, A. R., Gjerstorff, M. F., & Ditzel, H. J. (2024). Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with anti-PDL1 therapy effectively inhibits triple-negative breast cancer growth and metastasis. Molecular Cancer, 23(1), 6–6. https://doi.org/10.1186/s12943-023-01914-8.
5. Wang, Zheng-Xu, et al. “Combination of Chemotherapy and Immunotherapy for Colon Cancer in China: A Meta-Analysis.” World Journal of Gastroenterology : WJG, vol. 20, no. 4, 2014, pp. 1095–106, https://doi.org/10.3748/wjg.v20.i4.1095.
6. Lundqvist, Andreas, et al. “Adoptive Infusion of Ex Vivo Expanded Autologous Natural Killer (NK) Cells in Cancer Patients Treated with Bortezomib to Sensitize to NK-TRAIL Cytotoxicity.” Blood, vol. 114, no. 22, 2009, pp. 4080–4080, https://doi.org/10.1182/blood.V114.22.4080.4080.
7. Kaleta-Richter, Marta, et al. “The Capability and Potential of New Forms of Personalized Colon Cancer Treatment: Immunotherapy and Photodynamic Therapy.” Photodiagnosis and Photodynamic Therapy, vol. 25, 2019, pp. 253–58, https://doi.org/10.1016/j.pdpdt.2019.01.004.
8. Gao, Xin-Ying, and Xiu-Ling Wang. “An Adoptive T Cell Immunotherapy Targeting Cancer Stem Cells in a Colon Cancer Model.” Journal of B.U. ON., vol. 20, no. 6, 2015, pp. 1456–63.
9. Ren, J., Di, L., Song, G., Yu, J., Jia, J., Zhu, Y., Yan, Y., Jiang, H., Liang, X., Che, L., Zhang, J., Wan, F., Wang, X., Zhou, X., & Lyerly, H. K. (2013). Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences. Clinical & Translational Oncology, 15(10), 780–788. https://doi.org/10.1007/s12094-013-1001-9.

Disclaimer: The information on this website is for educational purposes only and not intended as medical advice. Always consult with a qualified healthcare provider for medical advice and treatment options.